TBIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TBIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Translate Bio's change in receivables for the quarter that ended in Jun. 2021 was $-0.8 Mil. It means Translate Bio's Accounts Receivable increased by $0.8 Mil from Mar. 2021 to Jun. 2021 .
Translate Bio's change in receivables for the fiscal year that ended in Dec. 2020 was $-22.0 Mil. It means Translate Bio's Accounts Receivable increased by $22.0 Mil from Dec. 2019 to Dec. 2020 .
Translate Bio's Accounts Receivable for the quarter that ended in Jun. 2021 was $0.0 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Translate Bio's Days Sales Outstanding for the three months ended in Jun. 2021 was 0.00.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Translate Bio's liquidation value for the three months ended in Jun. 2021 was $175.0 Mil.
The historical data trend for Translate Bio's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Translate Bio Annual Data | |||||||||||
Trend | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | ||||||
Change In Receivables | - | - | -0.83 | -3.76 | -22.00 |
Translate Bio Quarterly Data | |||||||||||||||||||
Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | |
Change In Receivables | Get a 7-Day Free Trial | -8.90 | -10.01 | -1.46 | 3.36 | -0.79 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.9 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Translate Bio (NAS:TBIO) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Translate Bio's Days Sales Outstanding for the quarter that ended in Jun. 2021 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0 | / | 72.649 | * | 91 |
= | 0.00 |
2. In Ben Graham's calculation of liquidation value, Translate Bio's accounts receivable are only considered to be worth 75% of book value:
Translate Bio's liquidation value for the quarter that ended in Jun. 2021 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 667.198 | - | 492.233 | + | 0.75 * 0 | + | 0.5 * 0 |
= | 175.0 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Translate Bio's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Jean Francois Formela | director | C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451 |
Renaud Ronald C Jr | director, officer: Chief Executive Officer, other: President | C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109 |
Paul D. Burgess | officer: Chief Operating Officer, CLO, other: Secretary | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Owen Hughes | director | C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139 |
Shire Human Genetic Therapies, Inc. | 10 percent owner | 300 SHIRE WAY LEXINGTON MA 02421 |
Takeda Pharmaceutical Co Ltd | 10 percent owner | 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668 |
Baupost Group Gp, L.l.c. | 10 percent owner | 10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116 |
Seth A Klarman | 10 percent owner | 10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116 |
Baupost Group Llc/ma | 10 percent owner | 10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116 |
George Demetri | director | BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142 |
Daniella Beckman | director | C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139 |
Robert M Plenge | director | C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421 |
Daniel Lynch | director | |
Robert J. Meyer | director | 2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713 |
Ann Barbier | officer: Chief Medical Officer | 255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109 |
From GuruFocus
By GlobeNewswire GlobeNewswire • 06-05-2023
By GuruFocusNews GuruFocusNews • 07-02-2022
By sperokesalga sperokesalga • 05-31-2023
By GlobeNewswire GlobeNewswire • 05-31-2023
By Marketwired • 08-10-2023
By GuruFocusNews GuruFocusNews • 07-09-2022
By sperokesalga sperokesalga • 04-27-2023
By sperokesalga sperokesalga • 02-16-2023
By PurpleRose PurpleRose • 08-02-2022
By sperokesalga sperokesalga • 03-31-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.